RECRUITING

Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study is looking at tumor tissue samples from patients who have undergone surgery for advanced stage III or stage IV ovarian epithelial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn how tumor infiltrating T cells can predict how patients will respond to treatment.

Official Title

Validation of Tumor-Infiltrating T-Cells as a Biomarker for Advanced Epithelial Ovarian Cancer

Quick Facts

Study Start:2004-09
Study Completion:N/A
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01000259

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of stage III or IV ovarian epithelial cancer and enrolled on Gynecologic Oncology Group (GOG)-0136 and a GOG front-line platinum/taxol chemotherapy trial (GOG-0114, GOG-132, GOG-0158, or GOG-0162)
  2. * Must have fixed and paraffin-embedded tissue from primary surgery available from 1 of the following sources:
  3. * Patients enrolled on GOG-0136 and a GOG front-line platinum/taxol chemotherapy trial(GOG-0114, GOG-0132, GOG-0158, and GOG-0162)
  4. * Patients who have had either optimal or suboptimal cytoreductive surgery
  5. * Patients for whom adequate demographic data, including major prognostic factors and follow-up information, were collected
  6. * Evaluable patients must have had measurable or nonmeasurable disease
  7. * Demographic and follow-up data available
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Principal Investigator

George Coukos
PRINCIPAL_INVESTIGATOR
Gynecologic Oncology Group

Study Locations (Sites)

Gynecologic Oncology Group
Philadelphia, Pennsylvania, 19103
United States

Collaborators and Investigators

Sponsor: Gynecologic Oncology Group

  • George Coukos, PRINCIPAL_INVESTIGATOR, Gynecologic Oncology Group

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2004-09
Study Completion DateN/A

Study Record Updates

Study Start Date2004-09
Study Completion DateN/A

Terms related to this study

Additional Relevant MeSH Terms

  • Stage IIIA Ovarian Cancer
  • Stage IIIB Ovarian Cancer
  • Stage IIIC Ovarian Cancer
  • Stage IV Ovarian Cancer